Aprea Therapeutics
APRE

$3.96

2.59%

Market Cap: 21.5M

About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

147% more capital invested

Capital invested by funds: $4.35M [Q4 2023] → $10.8M (+$6.41M) [Q1 2024]

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

21% more funds holding

Funds holding: 19 [Q4 2023] → 23 (+4) [Q1 2024]

18.68% more ownership

Funds ownership: 24.76% [Q4 2023] → 43.44% (+18.68%) [Q1 2024]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$11

178%

upside

Avg. target

$18.20

360%

upside

High target

$20

405%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	405%upside $20	Buy Reiterated	24 Jun 2024
HC Wainwright & Co. Joseph Pantginis	405%upside $20	Buy Reiterated	17 Jun 2024
HC Wainwright & Co. Joseph Pantginis	405%upside $20	Buy Reiterated	14 May 2024
Wedbush Robert Driscoll	178%upside $11	Outperform Maintained	27 Mar 2024
HC Wainwright & Co. Joseph Pantginis	405%upside $20	Buy Maintained	26 Mar 2024

See Analyst Rankings

Financial journalist opinion

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represents a key advancement in Aprea's clinical pipeline DOYLESTOWN, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the first patient has been dosed in the ACESOT-1051 Phase 1 study evaluating daily oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumor patients with unmet medical need.

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been found to be safe and well tolerated with no dose limiting toxicities (DLTs) observed DOYLESTOWN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment.

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows:

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company's IND application for the drug candidate APR-1051. Aprea has also secured funding up to USD 34 million through a financing round led by Sphera Healthcare. With the approval and financing in place, the company will be able to start the first clinical study with APR-1051.

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

See News Rankings